KR102977075B1 - 항체 약물 복합체, 이의 중간체, 제조 방법 및 용도 - Google Patents

항체 약물 복합체, 이의 중간체, 제조 방법 및 용도

Info

Publication number
KR102977075B1
KR102977075B1 KR1020227002873A KR20227002873A KR102977075B1 KR 102977075 B1 KR102977075 B1 KR 102977075B1 KR 1020227002873 A KR1020227002873 A KR 1020227002873A KR 20227002873 A KR20227002873 A KR 20227002873A KR 102977075 B1 KR102977075 B1 KR 102977075B1
Authority
KR
South Korea
Prior art keywords
antibody
sequence
amino acid
alkyl
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227002873A
Other languages
English (en)
Korean (ko)
Other versions
KR20220025861A (ko
Inventor
빈 바오
칭송 구오
베이 가오
이판 장
쉐페이 추이
통 양
이쥔 쉔
웬보 장
웨이 립
레이 왕
Original Assignee
상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 filed Critical 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드
Publication of KR20220025861A publication Critical patent/KR20220025861A/ko
Application granted granted Critical
Publication of KR102977075B1 publication Critical patent/KR102977075B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227002873A 2019-06-28 2020-06-05 항체 약물 복합체, 이의 중간체, 제조 방법 및 용도 Active KR102977075B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910577909.6 2019-06-28
CN201910577909 2019-06-28
PCT/CN2020/094767 WO2020259258A1 (zh) 2019-06-28 2020-06-05 一种抗体偶联药物、其中间体、制备方法及应用

Publications (2)

Publication Number Publication Date
KR20220025861A KR20220025861A (ko) 2022-03-03
KR102977075B1 true KR102977075B1 (ko) 2026-06-12

Family

ID=74059658

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002873A Active KR102977075B1 (ko) 2019-06-28 2020-06-05 항체 약물 복합체, 이의 중간체, 제조 방법 및 용도

Country Status (9)

Country Link
US (1) US20220233708A1 (enExample)
EP (1) EP3991754A4 (enExample)
JP (1) JP7407845B2 (enExample)
KR (1) KR102977075B1 (enExample)
CN (1) CN113766933B (enExample)
AU (1) AU2020301289B2 (enExample)
BR (1) BR112021026580A2 (enExample)
CA (1) CA3144790A1 (enExample)
WO (1) WO2020259258A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020402006A1 (en) * 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
BR112022024930A2 (pt) * 2020-06-08 2022-12-27 Baili Bio Chengdu Pharmaceutical Co Ltd Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo
WO2021252708A1 (en) * 2020-06-11 2021-12-16 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
JP7454110B2 (ja) * 2020-12-04 2024-03-21 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド 抗体薬物複合体、その中間体、製造方法及び使用
AU2021394411A1 (en) * 2020-12-11 2023-07-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Novel camptothecin derivative, composition containing same, and use thereof
WO2022126593A1 (zh) * 2020-12-18 2022-06-23 上海复旦张江生物医药股份有限公司 一种靶向trop2的抗体药物偶联物、其制备方法及应用
US20240058463A1 (en) * 2020-12-18 2024-02-22 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2022171115A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 用于adc制备的喜树碱衍生物
WO2022204947A1 (zh) * 2021-03-30 2022-10-06 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN116867789B (zh) * 2021-03-31 2025-06-24 上海复旦张江生物医药股份有限公司 一种伊喜替康衍生物的制备方法及其中间体
CN115385926B (zh) * 2021-05-24 2025-06-03 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
WO2022262789A1 (zh) * 2021-06-17 2022-12-22 明慧医药（杭州）有限公司 一种抗肿瘤化合物及其应用
CA3224492A1 (en) * 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN117715913A (zh) * 2021-07-19 2024-03-15 芝诺管理公司 免疫缀合物和方法
JP7892050B2 (ja) 2021-07-30 2026-07-17 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド 抗ｄｌｌ３抗体とその製造方法、その薬物複合体及び使用
US20240390512A1 (en) * 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
CA3233254A1 (en) * 2021-09-27 2023-03-30 Evopoint Biosciences Co., Ltd. Antibody, antibody-drug conjugate thereof and use thereof
JP7767613B2 (ja) * 2021-11-15 2025-11-11 システィミューン，インコーポレイテッド 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
WO2023103854A1 (zh) * 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES
CN118955614B (zh) * 2022-07-05 2025-12-30 上海药明合联生物技术有限公司 偶联连接子
EP4558506A1 (en) * 2022-07-22 2025-05-28 NJ Bio, Inc. Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
CN119546344A (zh) * 2022-07-27 2025-02-28 明慧医药（杭州）有限公司 抗体药物偶联物及其应用
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
KR20250111373A (ko) * 2022-11-25 2025-07-22 밍훼이 파마슈티컬 (항저우) 리미티드 항종양 화합물 및 이의 응용
IL321037A (en) * 2022-11-30 2025-07-01 Shanghai Chia Tai Tianqing Pharmaceutical Tech Development Co Ltd Anti-cldn18.2 antibody-drug conjugate, and pharmaceutical composition thereof and use thereof
CN116217655B (zh) * 2022-12-30 2025-09-23 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的中间体的制备方法
CN116217654B (zh) * 2022-12-30 2025-09-26 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN116178386B (zh) * 2022-12-30 2025-09-09 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN121038817A (zh) 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
CN119371430A (zh) * 2023-07-26 2025-01-28 上海医药集团股份有限公司 喜树碱类小分子及其抗体药物偶联物、制备方法和应用
KR20260060334A (ko) * 2023-08-25 2026-05-04 마크로제닉스, 인크. B7-h3 항체-약물 접합체
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
CN122374343A (zh) 2023-11-30 2026-07-10 江苏康宁杰瑞生物制药有限公司 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途
AU2024415931A1 (en) 2023-12-27 2026-07-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Multi-specific antibody targeting her3 and trop2 and conjugate thereof
TW202612739A (zh) 2024-05-16 2026-04-01 日商第一三共股份有限公司 抗ｂ７－ｈ３抗體－藥物結合物與雄性素受體傳訊抑制劑之組合
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
CN120617538B (zh) * 2025-07-21 2026-04-03 南京滴力生物科技有限公司 一种用于治疗肿瘤的抗体药物偶联物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173337A2 (en) 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN104755494B (zh) 2012-10-11 2018-09-07 第一三共株式会社 抗体－药物偶联物
WO2019031615A1 (ja) 2017-08-10 2019-02-14 大日本住友製薬株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2240495B1 (en) * 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
NZ588884A (en) * 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
HUE035798T2 (en) * 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
SG11201603960XA (en) * 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
US20190209704A1 (en) * 2014-10-20 2019-07-11 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions and methods of use
CN109106951A (zh) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
CN109200291B (zh) * 2018-10-24 2021-06-08 中国医学科学院医药生物技术研究所 一种靶向于egfr的抗体偶联药物及其制备方法和其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173337A2 (en) 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN104755494B (zh) 2012-10-11 2018-09-07 第一三共株式会社 抗体－药物偶联物
WO2019031615A1 (ja) 2017-08-10 2019-02-14 大日本住友製薬株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体

Also Published As

Publication number Publication date
JP7407845B2 (ja) 2024-01-04
KR20220025861A (ko) 2022-03-03
AU2020301289A1 (en) 2022-02-24
US20220233708A1 (en) 2022-07-28
WO2020259258A1 (zh) 2020-12-30
CN113766933A (zh) 2021-12-07
BR112021026580A2 (pt) 2022-05-03
EP3991754A1 (en) 2022-05-04
CN113766933B (zh) 2024-09-06
AU2020301289B2 (en) 2024-11-07
EP3991754A4 (en) 2023-05-17
CA3144790A1 (en) 2020-12-30
JP2022542222A (ja) 2022-09-30

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)